Do analysts recommend XBIO or BCAB?

BioAtla has a consensus target price of $200.00, indicating a potential upside of 15,051.52%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioAtla 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate BCAB or OSRH?

BioAtla currently has a consensus price target of $200.00, indicating a potential upside of 15,051.52%. Given BioAtla's stronger consensus rating and higher possible upside, equities research analysts plainly believe BioAtla is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, BCAB or OSRH?

OSR has lower revenue, but higher earnings than BioAtla. OSR is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioAtla $8.50M 0.26 -$59.61M -$25.45 N/A OSR $1.81M 4.37 -$27.06M -$0.37 N/A

Is BCAB or OSRH more profitable?

BioAtla has a net margin of 0.00% compared to OSR's net margin of -593.15%. BioAtla's return on equity of 0.00% beat OSR's return on equity. Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -289.67% OSR -593.15% -8.36% -6.24%

Is IMNN or BCAB more profitable?

BioAtla's return on equity of 0.00% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Imunon N/A -358.01% -132.91% BioAtla N/A N/A -289.67%

Is BCAB or MTVA more profitable?

BioAtla's return on equity of 0.00% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -289.67% MetaVia N/A -209.67% -107.91%

Do analysts rate IMRN or BCAB?

BioAtla has a consensus price target of $200.00, indicating a potential upside of 15,051.52%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioAtla 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, IMRN or BCAB?

Immuron has higher earnings, but lower revenue than BioAtla. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuron $5.47M 2.66 -$2.72M N/A N/A BioAtla $8.50M 0.26 -$59.61M -$25.45 N/A

Is IMRN or BCAB more profitable?

Company Net Margins Return on Equity Return on Assets Immuron N/A N/A N/A BioAtla N/A N/A -289.67%

BioAtla (BCAB) Competitors

$1.32 +0.02 (+1.54%)

As of 03:59 PM Eastern

Compare

BCAB vs. XBIO, OSRH, IMNN, MTVA, and IMRN

Should you buy BioAtla stock or one of its competitors? BioAtla's main competitors and comparable companies include Xenetic Biosciences (XBIO), OSR (OSRH), Imunon (IMNN), MetaVia (MTVA), and Immuron (IMRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioAtla compare to Xenetic Biosciences?

Xenetic Biosciences (NASDAQ:XBIO) and BioAtla (NASDAQ:BCAB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

BioAtla has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -75.90%. BioAtla's return on equity of 0.00% beat Xenetic Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-75.90%	-40.62%	-34.97%
BioAtla	N/A	N/A	-289.67%

BioAtla has a consensus target price of $200.00, indicating a potential upside of 15,051.52%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by company insiders. Comparatively, 9.3% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Xenetic Biosciences has higher earnings, but lower revenue than BioAtla. Xenetic Biosciences is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$2.98M	3.59	-$2.68M	-$1.16	N/A
BioAtla	$8.50M	0.26	-$59.61M	-$25.45	N/A

In the previous week, Xenetic Biosciences' average media sentiment score of 0.00 equaled BioAtla'saverage media sentiment score.

Company	Overall Sentiment
Xenetic Biosciences	Neutral
BioAtla	Neutral

Xenetic Biosciences has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market. Comparatively, BioAtla has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market.

Summary

BioAtla beats Xenetic Biosciences on 9 of the 14 factors compared between the two stocks.

How does BioAtla compare to OSR?

BioAtla (NASDAQ:BCAB) and OSR (NASDAQ:OSRH) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

77.2% of BioAtla shares are held by institutional investors. Comparatively, 55.3% of OSR shares are held by institutional investors. 9.3% of BioAtla shares are held by company insiders. Comparatively, 36.9% of OSR shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

OSR has lower revenue, but higher earnings than BioAtla. OSR is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$8.50M	0.26	-$59.61M	-$25.45	N/A
OSR	$1.81M	4.37	-$27.06M	-$0.37	N/A

BioAtla has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, OSR has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market.

BioAtla has a net margin of 0.00% compared to OSR's net margin of -593.15%. BioAtla's return on equity of 0.00% beat OSR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-289.67%
OSR	-593.15%	-8.36%	-6.24%

In the previous week, BioAtla's average media sentiment score of 0.00 equaled OSR'saverage media sentiment score.

Company	Overall Sentiment
BioAtla	Neutral
OSR	Neutral

BioAtla currently has a consensus price target of $200.00, indicating a potential upside of 15,051.52%. Given BioAtla's stronger consensus rating and higher possible upside, equities research analysts plainly believe BioAtla is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

BioAtla beats OSR on 9 of the 14 factors compared between the two stocks.

How does BioAtla compare to Imunon?

Imunon (NASDAQ:IMNN) and BioAtla (NASDAQ:BCAB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Imunon currently has a consensus price target of $10.00, suggesting a potential upside of 532.91%. BioAtla has a consensus price target of $200.00, suggesting a potential upside of 15,051.52%. Given BioAtla's higher probable upside, analysts clearly believe BioAtla is more favorable than Imunon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Imunon has higher earnings, but lower revenue than BioAtla. Imunon is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Imunon	N/A	N/A	-$14.49M	-$3.83	N/A
BioAtla	$8.50M	0.26	-$59.61M	-$25.45	N/A

Imunon has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market. Comparatively, BioAtla has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

BioAtla's return on equity of 0.00% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Imunon	N/A	-358.01%	-132.91%
BioAtla	N/A	N/A	-289.67%

In the previous week, Imunon's average media sentiment score of 0.00 equaled BioAtla'saverage media sentiment score.

Company	Overall Sentiment
Imunon	Neutral
BioAtla	Neutral

4.5% of Imunon shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 2.8% of Imunon shares are owned by company insiders. Comparatively, 9.3% of BioAtla shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

BioAtla beats Imunon on 6 of the 10 factors compared between the two stocks.

How does BioAtla compare to MetaVia?

BioAtla (NASDAQ:BCAB) and MetaVia (NASDAQ:MTVA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

In the previous week, BioAtla's average media sentiment score of 0.00 equaled MetaVia'saverage media sentiment score.

Company	Overall Sentiment
BioAtla	Neutral
MetaVia	Neutral

77.2% of BioAtla shares are owned by institutional investors. Comparatively, 1.4% of MetaVia shares are owned by institutional investors. 9.3% of BioAtla shares are owned by insiders. Comparatively, 0.6% of MetaVia shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

BioAtla's return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-289.67%
MetaVia	N/A	-209.67%	-107.91%

BioAtla has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, MetaVia has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

BioAtla presently has a consensus target price of $200.00, indicating a potential upside of 15,051.52%. MetaVia has a consensus target price of $20.00, indicating a potential upside of 1,042.86%. Given BioAtla's higher possible upside, equities research analysts plainly believe BioAtla is more favorable than MetaVia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MetaVia has lower revenue, but higher earnings than BioAtla. MetaVia is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$8.50M	0.26	-$59.61M	-$25.45	N/A
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A

Summary

BioAtla beats MetaVia on 6 of the 10 factors compared between the two stocks.

How does BioAtla compare to Immuron?

Immuron (NASDAQ:IMRN) and BioAtla (NASDAQ:BCAB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
BioAtla	N/A	N/A	-289.67%

0.1% of Immuron shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 7.0% of Immuron shares are held by insiders. Comparatively, 9.3% of BioAtla shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Immuron has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, BioAtla has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market.

In the previous week, Immuron had 9 more articles in the media than BioAtla. MarketBeat recorded 9 mentions for Immuron and 0 mentions for BioAtla. Immuron's average media sentiment score of 0.89 beat BioAtla's score of 0.00 indicating that Immuron is being referred to more favorably in the media.

Company	Overall Sentiment
Immuron	Positive
BioAtla	Neutral

BioAtla has a consensus price target of $200.00, indicating a potential upside of 15,051.52%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Immuron has higher earnings, but lower revenue than BioAtla.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$5.47M	2.66	-$2.72M	N/A	N/A
BioAtla	$8.50M	0.26	-$59.61M	-$25.45	N/A

Summary

Immuron and BioAtla tied by winning 6 of the 12 factors compared between the two stocks.

Get BioAtla News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCAB vs. The Competition

Export

Metric	BioAtla	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.20M	$3.98B	$7.17B	$12.88B
Dividend Yield	N/A	3.60%	2.53%	8.57%
P/E Ratio	-0.05	12.71	272.99	25.40
Price / Sales	0.26	1,325.73	612.73	97.75
Price / Cash	N/A	106.87	77.82	52.27
Price / Book	-0.05	16.15	12.85	6.17
Net Income	-$59.61M	-$22.76M	$3.47B	$349.50M
7 Day Performance	-24.14%	1.13%	1.24%	-0.05%
1 Month Performance	-60.60%	8.93%	5.81%	0.80%
1 Year Performance	-94.71%	52.96%	25.75%	15.62%

BioAtla Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCAB BioAtla	1.3084 of 5 stars	$1.32 +1.5%	$200.00 +15,051.5%	-94.7%	$2.20M	$8.50M	N/A	60	Gap Down
XBIO Xenetic Biosciences	0.2648 of 5 stars	$4.12 -1.7%	N/A	+52.6%	$9.44M	$2.98M	N/A	4	Gap Up
OSRH OSR	0.3378 of 5 stars	$0.26 -5.5%	N/A	-59.2%	$9.13M	$1.81M	N/A	N/A	Gap Down
IMNN Imunon	2.3243 of 5 stars	$1.63 -0.3%	$10.00 +515.4%	-72.8%	$9.12M	N/A	N/A	30
MTVA MetaVia	1.5137 of 5 stars	$1.68 -2.3%	$20.00 +1,090.5%	-75.0%	$8.67M	N/A	N/A	8	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCAB) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioAtla (BCAB) Competitors

BCAB vs. XBIO, OSRH, IMNN, MTVA, and IMRN

How does BioAtla compare to Xenetic Biosciences?

Summary

How does BioAtla compare to OSR?

Summary

How does BioAtla compare to Imunon?

Summary

How does BioAtla compare to MetaVia?

Summary

How does BioAtla compare to Immuron?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioAtla (BCAB) Competitors

BCAB vs. XBIO, OSRH, IMNN, MTVA, and IMRN

How does BioAtla compare to Xenetic Biosciences?

Is XBIO or BCAB more profitable?

Do analysts recommend XBIO or BCAB?

Do institutionals and insiders believe in XBIO or BCAB?

Which has better valuation and earnings, XBIO or BCAB?

Does the media favor XBIO or BCAB?

Which has more risk and volatility, XBIO or BCAB?

Summary

How does BioAtla compare to OSR?

Do institutionals and insiders believe in BCAB or OSRH?

Which has better valuation & earnings, BCAB or OSRH?

Which has more risk & volatility, BCAB or OSRH?

Is BCAB or OSRH more profitable?

Does the media refer more to BCAB or OSRH?

Do analysts rate BCAB or OSRH?

Summary

How does BioAtla compare to Imunon?

Do analysts recommend IMNN or BCAB?

Which has preferable earnings and valuation, IMNN or BCAB?

Which has more volatility & risk, IMNN or BCAB?

Is IMNN or BCAB more profitable?

Does the media favor IMNN or BCAB?

Do institutionals & insiders have more ownership in IMNN or BCAB?

Summary

How does BioAtla compare to MetaVia?

Does the media refer more to BCAB or MTVA?

Do institutionals & insiders have more ownership in BCAB or MTVA?

Is BCAB or MTVA more profitable?

Which has more risk and volatility, BCAB or MTVA?

Do analysts rate BCAB or MTVA?

Which has stronger earnings and valuation, BCAB or MTVA?

Summary

How does BioAtla compare to Immuron?

Is IMRN or BCAB more profitable?

Do institutionals and insiders believe in IMRN or BCAB?

Which has more volatility & risk, IMRN or BCAB?

Does the media favor IMRN or BCAB?

Do analysts rate IMRN or BCAB?

Which has stronger earnings and valuation, IMRN or BCAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools